WS Management’s Silence Therapeutics SLN Stock Holding History

WS Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$155K	–	70
2023 Q1	$155K	Hold	25,000	–	–	0.02%	58
2022 Q4	$381K	Hold	25,000	–	–	0.03%	62
2022 Q3	$251K	Hold	25,000	–	–	0.02%	68
2022 Q2	$296K	Buy	+25,000	New	+$304K	0.02%	72

Other funds holding SLN

LOAME

Lombard Odier Asset Management (Europe) London, United Kingdom $1.85B AUM 27.05% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

WS Management's SLN Position: Q2 2023 in Review

WS Management sold out of Silence Therapeutics (SLN) in Q2 2023, closing a stake of 25,000 shares — an estimated $155K sold.

WS Management first reported a position in SLN in Q2 2022 and held it in 4 quarters. The position peaked at $381K in Q4 2022. 29 funds tracked by Wall St. Rank hold SLN as of Q2 2023.

WS Management reported no remaining Silence Therapeutics position as of Q2 2023 after selling out during the quarter.
WS Management sold 25,000 Silence Therapeutics shares in Q2 2023, an estimated $155K.
WS Management first reported a position in Silence Therapeutics in Q2 2022 and held it in 4 quarters.
WS Management's Silence Therapeutics position peaked at $381K in Q4 2022.
29 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2023.

Based on WS Management's 13F filing for Q2 2023, filed 10 Aug 2023.